MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
*[[Media:2019_06-25_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 25, 2019]] | |||
*[[Media:2019_05-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 28, 2019]] | *[[Media:2019_05-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 28, 2019]] | ||
*[[Media:2019_04-23_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 23, 2019]] | *[[Media:2019_04-23_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 23, 2019]] | ||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 16:33, 24 September 2019
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive